Norepinephrine Transporter Imaging in Addiction Disorders



Status:Active, not recruiting
Conditions:Obesity Weight Loss, Psychiatric
Therapuetic Areas:Endocrinology, Psychiatry / Psychology
Healthy:No
Age Range:18 - 50
Updated:1/11/2019
Start Date:July 2007
End Date:July 2019

Use our guide to learn which trials are right for you!

In this study we propose to study 24 unmedicated abstinent alcohol dependent patients, 24
obese individuals and 24 individually matched healthy control subjects and determine
Norepinephrine Transporter (NET) expression in vivo using (S,S)-[11C]MRB and PET.

In this study we propose to study 24 unmedicated abstinent alcohol dependent patients, 24
obese individuals and 24 individually matched healthy control subjects and determine NET
expression in vivo using (S,S)-[11C]MRB and PET. This will provide novel insight into
alterations in pre- and post-synaptic homeostasis in alcoholism and obese people with the
goal to explain regulatory processes and their alterations in these disorders. A better
understanding of brain mechanisms and contributory stress would have an enormous impact on
the public's understanding of the vulnerabilities for these disorders, influence medical and
legal response to these problems, could lead to a new understanding of these phenomena, and
stimulate a better means of prevention and treatment.

Inclusion Criteria:

1. age 18-50 years inclusive;

2. able to read and write English;

3. for women, being in follicular phase of menstrual cycle at the time of the PET scan as
determined by calculating the time since the last menses and assessments of serum
hormone levels;

4. 30 < BMI < 35 for obese subjects (upper limit of 35 selected given our experience with
heavier individuals fitting comfortably in the MRI scanner) and 18.5 < BMI <25 for
normal weight subjects, and no recent weight changes in prior 12 weeks prior to the
study;

5. for alcohol dependent patients meet current DSM-IV criteria for alcohol dependence or
being in partial remission; abstinence on the MRI and PET scan days will be determined
by patient self-report, breath alcohol tests (BACs) conducted during inpatient stay at
the CNRU/GCRC, participants have to be non-obese BMI < 30, and

6. for current daily smokers, having smoked 10 or more cigarettes daily for the past year
and CO level > 10 ppm at intake; for non-smokers, no tobacco consumption for more than
one year and never having used tobacco daily.

Exclusion Criteria:

1. any major neurological illness or injury and any current or prior clinically
significant mental health or substance use disorder (with possible exception of
nicotine dependence and alcohol dependence per the inclusion criteria) as determined
by SCID interview and the judgement of the PI;

2. use of any psychoactive medication within past three weeks;

3. any significant unstable medical condition such as asthma or heart disease which may
limit the interpretation of the imaging results, for example due to changes in tracer
delivery in hypertensive patients;

4. IQ<70 based on past intelligence testing;

5. any metal in body that would pose a risk with MRI; and

6. claustrophobia that would interfere with MRI or PET imaging;

7. presence of alcohol and drug use in the 72 hours prior to scanning, with the exception
of tobacco;

8. pregnancy or nursing for women,

9. peri- and post- menopausal women, and those with ovarectomies will be excluded

10. current eating disorders, including binge eating.
We found this trial at
1
site
333 Cedar St
New Haven, Connecticut 06504
(203) 432-4771
Yale University School of Medicine Founded in 1810, the Yale School of Medicine is a...
?
mi
from
New Haven, CT
Click here to add this to my saved trials